Browsing publications by Dr Michela Guglieri

Newcastle AuthorsTitleYear
Dr Michela Guglieri
Dr Rita Barresi
Professor Katherine Bushby
Professor Volker Straub
Biochemical Characterization of Patients With In-Frame or Out-of-Frame DMD Deletions Pertinent to Exon 44 or 45 Skipping2014
Dr Amina Chaouch
Dr Michela Guglieri
Professor Volker Straub
Professor Hanns Lochmuller
Fibronectin is a serum biomarker for Duchenne muscular dystrophy2014
Dr Michela Guglieri
Dr Henriette van Ruiten
Professor Volker Straub
Professor Katherine Bushby
Improving the diagnosis of Duchenne muscular dystrophy2014
Professor Volker Straub
Dr Michelle Eagle
Dr Michela Guglieri
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study2014
Dr Anna Sarkozy
Dr Debbie Hicks
Dr Steven Laval
Dr Rita Barresi
Dr Lizzie Harris
et al.
ANO5 Gene Analysis in a Large Cohort of Patients with Anoctaminopathy: Confirmation of Male Prevalence and High Occurrence of the Common Exon 5 Gene Mutation2013
Professor Helen McConachie
Professor Ann Le Couteur
Dr Michela Guglieri
Professor Katherine Bushby
Emotional impact of genetic trials in progressive paediatric disorders: a dose-ranging exon-skipping trial in Duchenne muscular dystrophy2013
Dr Michela Guglieri
Dr Rita Barresi
Professor Katherine Bushby
Professor Volker Straub
Biochemical and clinical variability of Becker muscular dystrophy: Predicting optimal target exons for exon skipping therapy in Duchenne muscular dystrophy2012
Dr Michela Guglieri
Dr Michelle Eagle
Professor Katherine Bushby
Body mass index (BMI) and growth in Duchenne Muscular Dystrophy (DMD)2011
Dr Michela Guglieri
Professor Katherine Bushby
Professor Volker Straub
Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.2011
Dr Michela Guglieri
Dr John Bourke
Professor Volker Straub
Professor Katherine Bushby
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.2011
123